PI     PL

 

PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA- mutated, advanced or metastatic breast cancer following progression on or after an endocrinebased regimen.

 
×

Medical Information Request

×

Ask Speakers